---
id: ITE-2022-054
type: ITE
year: 2022
number: 54
created: 2025-08-08 07:54:57.696700
tags:
- ITE
- question
- ITE-2022
answer: A
topic: null
related_articles:
- title: Preconception Counseling and Care.
  path: 2023/2023-12-preconception-counseling-and-care.md
  similarity: 0.5
  link: '[[2023/2023-12-preconception-counseling-and-care|Preconception Counseling
    and Care.]]'
- title: 'Office-Based Urinalysis: A Comprehensive Review.'
  path: 2022/2022-07-office-based-urinalysis-a-comprehensive-review.md
  similarity: 0.474
  link: '[[2022/2022-07-office-based-urinalysis-a-comprehensive-review|Office-Based
    Urinalysis: A Comprehensive Review.]]'
- title: Additional Information on the Management of Infants Born to Mothers With
    HIV Infection.
  path: 2022/2022-08-additional-information-on-the-management-of-infants-born-to.md
  similarity: 0.467
  link: '[[2022/2022-08-additional-information-on-the-management-of-infants-born-to|Additional
    Information on the Management of Infants Born to Mothers With HIV Infection.]]'
- title: Perinatal Care of Transgender Patients, Adolescent Patients, and Patients
    With Opioid Use Disorder.
  path: 2022/2022-12-perinatal-care-of-transgender-patients-adolescent-patients-a.md
  similarity: 0.462
  link: '[[2022/2022-12-perinatal-care-of-transgender-patients-adolescent-patients-a|Perinatal
    Care of Transgender Patients, Adolescent Patients, and Patients With Opioid Use
    Disorder.]]'
- title: Cabotegravir (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection.
  path: 2023/2023-05-cabotegravir-apretude-for-pre-exposure-prophylaxis-for-hiv-t.md
  similarity: 0.462
  link: '[[2023/2023-05-cabotegravir-apretude-for-pre-exposure-prophylaxis-for-hiv-t|Cabotegravir
    (Apretude) for Pre-exposure Prophylaxis for HIV Type 1 Infection.]]'
topics:
- Nephrology
- Obstetrics/Gynecology
- Pharmacology
related_articles_2023_2025:
- title: afp clinical answers
  path: 2023/12/2023-12-afp-clinical-answers.md
  similarity: 0.514
  link: '[[2023/12/2023-12-afp-clinical-answers|afp clinical answers]]'
- title: afp clinical answers
  path: 2024/06/2024-06-afp-clinical-answers.md
  similarity: 0.505
  link: '[[2024/06/2024-06-afp-clinical-answers|afp clinical answers]]'
- title: practice guidelines headache pregnancy ureastfeeding
  path: 2023/07/2023-07-practice-guidelines-headache-pregnancy-breastfeeding.md
  similarity: 0.411
  link: '[[2023/07/2023-07-practice-guidelines-headache-pregnancy-breastfeeding|practice
    guidelines headache pregnancy ureastfeeding]]'
- title: afp clinical answers
  path: 2024/01/2024-01-afp-clinical-answers.md
  similarity: 0.405
  link: '[[2024/01/2024-01-afp-clinical-answers|afp clinical answers]]'
- title: prenatal care
  path: 2023/08/2023-08-prenatal-care.md
  similarity: 0.404
  link: '[[2023/08/2023-08-prenatal-care|prenatal care]]'
last_updated: '2025-08-10T20:27:41.408818'
---

# Question ITE-2022-054

periods. Menarche occurred at age 11, and by age 12 her menses were regular but quite painful. She misses at least 1 day of school each month due to the discomfort. She has tried acetaminophen/caffeine/pyrilamine (Midol Complete) and ibuprofen, 200 mg, without much relief. She is not sexually active. Her past medical history and surgical history are unremarkable. A urine pregnancy test is negative. Which one of the following would be the most appropriate next step for this patient?

## Options

**A.** Empiric treatment with maximum-dose naproxen

**B.** Screening for sexually transmitted infections

**C.** A pelvic examination

**D.** Pelvic ultrasonography

**E.** Referral to a gynecologist

## Answer

**A**

## Explanation

Dysmenorrhea affects 50%–90% of females and the great majority of cases are primary (see [[Articles/2023/2023-05-diabetes-management-primary-care.md|Diabetes Management in Primary Care: Evidence-Based Approaches]]) dysmenorrhea,
or pain that occurs in the absence of pelvic pathology. After a complete history confirming cyclic cramping
pelvic pain beginning around the start of menses and a negative urine pregnancy test, empiric treatment
should be offered (SOR C). First-line treatment is an NSAID at moderate to maximum dosing, such as
naproxen, 500 mg every 12 hours. Any NSAID can be used and should be started 1–2 days before the
onset of menses and continued through the first several days of bleeding. A secondary benefit to NSAID
use is a reduction in heavy menstrual bleeding. Combined estrogen/progestin oral contraceptives may also
be used as first-line therapy or in conjunction with NSAIDs.
While screening for sexually transmitted infections is important for sexually active adolescents, it is not
indicated in the evaluation of dysmenorrhea. Neither pelvic examination nor imaging is indicated when the
history is ...



## Related Articles

- [[Articles/2023/2023-05-diabetes-management-primary-care.md|Diabetes Management in Primary Care: Evidence-Based Approaches]]

## References

- Am Fam Physician  2021;104(2):164-170.
